
Secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was more effective in treating moderate-to-severe plaque psoriasis than the anti-tumor necrosis factor etanercept and current standard of care, according to a head-to-head phase 3 study.Data from the presented at the 22nd Congress of the European Association of Dermatology and Venereology (EADV) in Istanbul showed that secukinumab was effective in treating psoriasis, with rapid onset and durable responses, and may represent a new treatment alternative for patients.